Rethinking nutritional villains: A trans-fatty acid identified to boost immunotherapy

Keywords

CD8+ T cell / immunotherapy / trans-vaccenic acid

References

[1] Islam MA, Amin MN, Siddiqui SA, Hossain MP, Sultana F, Kabir MR. Trans fatty acids and lipid profile: a serious risk factor to cardiovascular disease, cancer and diabetes. Diabetes Metab Syndr. 2019;13:1643-1647.

[2] Pipoyan D, Stepanyan S, Stepanyan S, et al. The effect of trans fatty acids on human health: regulation and consumption patterns. Foods. 2021;10:2452.

[3] Fan H, Xia S, Xiang J, et al. Trans-vaccenic acid reprograms CD8⁺ T cells and anti-tumour immunity. Nature. 2023;623:1034-1043.

[4] Yakoob MY, Shi P, Willett WC, et al. Circulating biomarkers of dairy fat and risk of incident diabetes mellitus among men and women in the United States in two large prospective cohorts. Circulation. 2016;133:1645-1654.

[5] Kleber ME, Delgado GE, Lorkowski S, März Wvon Schacky C. Trans-fatty acids and mortality in patients referred for coronary angiography: the Ludwigshafen Risk and Cardiovascular Health Study. Eur Heart J. 2016;37:1072-1078.

[6] Tian Z, Liu M, Zhang Y, Wang X. Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies. J Hematol Oncol. 2021;14:75.

[7] Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023;20:359-371.

RIGHTS & PERMISSIONS

2024 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.